# Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment

> **NCT02149537** · PHASE4 · COMPLETED · sponsor: **Loyola University** · enrollment: 53 (actual)

## Conditions studied

- Sickle Cell Disease
- Sickle Cell Anemia

## Interventions

- **DRUG:** hydroxyurea

## Key facts

- **NCT ID:** NCT02149537
- **Lead sponsor:** Loyola University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2017-09
- **Final completion:** 2022-12
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2023-03-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02149537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02149537, "Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02149537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*